0
No votes yet
Article

Neurotoxicology of Chemotherapy in Relation to Cytokine Release, the Blood-Brain Barrier, and Cognitive Impairment

Jamie S. Myers
Janet Pierce
Thomas Pazdernik
ONF 2008, 35(6), 916-920 DOI: 10.1188/08.ONF.916-920

Purpose/Objectives: To review the effects of chemotherapeutic agents on the blood-brain barrier as related to cytokine release and cognitive impairment.

Data Sources: PubMed database.

Data Synthesis: The recent findings that standard doses of chemotherapy agents reach higher than expected levels in the brain and cerebral spinal fluid are being investigated as a potential etiology for the cognitive impairment seen in patients receiving chemotherapy for cancer. Chemotherapy and chemotherapy-related neurotoxicity are associated with the release of proinflammatory cytokines, substances related to sickness behavior (e.g., decreased ability to concentrate). Chemotherapy-related oxidative stress is an additional mechanism hypothesized to induce cognitive impairment. Cognitive impairment from chemotherapy is estimated to occur in 17%-75% of patients, and 17%-35% may suffer from long-term effects.

Conclusions: Further research is needed to identify the patients most at risk for cognitive impairment from chemotherapy. Prospective studies that evaluate appropriate interventions and control for age, intelligence quotient, education level, hormonal status, fatigue, anxiety, depression, chemotherapy regimen, and genetic status are needed.

Implications for Nursing: Changes in cognitive function are associated with significant effects on patients' quality of life. Oncology nurses must be aware of chemotherapy's effects on the brain to appropriately assess and educate patients and their families. In addition, nurses should develop plans of care to prevent or manage chemotherapy-related cognitive impairment after more intervention information is obtained.

References 

Ahles, T. A., & Saykin, A. J. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. <i>Cancer Investigation, 19</i>(8), 812-820.

Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. <i>Nature Reviews. Cancer, 7</i>(3), 192-201.

Barton, D., & Loprinzi, C. (2002). Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art of the possible. <i>Clinical Breast Cancer, 3</i>(Suppl. 3), S121-S127.

Brown, R. C., & Davis, T. P. (2002). Calcium modulation of adherens and tight junction function. <i>Stroke, 33</i>(6), 1706-1711.

Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. <i>Molecular Interventions, 7</i>(3), 147-156.

Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. A., et al. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. <i>Cancer, 97</i>(11), 2919-2925.

De La Garza, R., II. (2005). Endotoxin- or proinflammatory cytokine-induced sickness behavior as an animal model of depression: Focus on anhedonia. <i>Neuroscience and Biobehavioral Reviews, 29</i>(4-5), 761-770.

Espejo, C., & Martin, R. (2007). Pharmacology of inflammation. In D. R. Sibley, I. Hanin, M. Kuhar, & P. Skolnick (Eds.), <i>Handbook of contemporary neuropharmacology</i> (vol. 3, pp. 621-646). Hoboken, NJ: John Wiley and Sons.

Gietema, J. A., Meinardi, M. T., Messerschmidt, J., Gelevert, T., Alt, F., Uges, D. R., et al. (2000). Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. <i>Lancet, 355</i>(9209), 1075-1076.

Grigsby, J., Kaye, K., Kowalsky, J., & Kramer, A. M. (2002). Association of behavioral self-regulation with concurrent functional capacity among stroke rehabilitation patients. <i>Journal of Clinical Geropsychology, 8</i>(1), 25-33.

Kronfol, Z., & Remick, D. G. (2000). Cytokines and the brain: Implications for clinical psychiatry. <i>American Journal of Psychiatry, 158</i>(7), 683-694.

Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. <i>Neuroimmunomodulation, 11</i>(5), 279-292.

Maier, S. F. (2003). Bidirectional immune-brain communication: Implications for understanding stress, pain, and cognition. <i>Brain, Behavior, and Immunity, 17</i>(2), 69-85.

Maier, S. F., & Watkins, L. R. (1998). Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. <i>Psychological Review, 105</i>(1), 83-107.

Maier, S. F., & Watkins, L. R. (2003). Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. <i>Brain, Behavior, and Immunity, 17</i>(Suppl. 1), S125-S131.

Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. <i>Annals of Oncology, 17</i>(1), 146-150.

Miller, A. H. (2003). Cytokines and sickness behavior: Implications for cancer care and control. <i>Brain, Behavior, and Immunity, 17</i>(Suppl. 1), S132-S134.

Niiya, M., Niiya, K., Kiguchi, T., Shibakura, M., Asaumi, N., Shinagawa, K., et al. (2003). Induction of TNF-alpha, uPA, IL-8, and MCP-1 by doxorubicin in human lung cancer cells. <i>Cancer Chemotherapy and Pharmacology, 52</i>(5), 391-398.

O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. <i>Seminars in Oncology Nursing, 19</i>(4, Suppl. 2), 17-24.

Parnet, P., Kelley, K. W., Bluthe, R. M., & Dantzer, R. (2002). Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. <i>Journal of Neuroimmunology, 125</i>(1-2), 5-14.

Pollmacher, T., Haack, M., Schuld, A., Reichenberg, A., & Yirmiya, R. (2002). Low levels of circulating inflammatory cytokines—Do they affect human brain functions? <i>Brain, Behavior, and Immunity, 16</i>(5), 525-532.

Saykin, A. J., Ahles, T. A., & McDonald, B. C. (2003). Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. <i>Seminars in Clinical Neuropsychiatry, 8</i>(4), 201-216.

Shapiro, P. J., Jacobs, A. R., Palmer, S. C., Coyne, J. C., Meadows, A. T., & Vaughn, D. J. (2005). Neurocognitive function in long-term survivors of testicular cancer. <i>Journal of Clinical Oncology, 23</i>(Suppl. 16), 8034.

Tangpong, J., Cole, M. P., Sultana, R., Estus, S., Vore, M. C., St. Clair, W., et al. (2007). Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. <i>Journal of Neurochemistry, 100</i>(1), 191-201.

Tannock, I. F., Ahles, T. A., Ganz, P. A., & Van Dam, F. S. (2004). Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. <i>Journal of Clinical Oncology, 22</i>(11), 2233-2239.

Troy, L., McFarland, K., Littman-Power, S., Kelly, B. J., Walpole, E. T., Wyld, D., et al. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. <i>Psycho-Oncology, 9</i>(1), 29-39.

Tuxen, M. K., & Hansen, S. W. (1994). Neurotoxicity secondary to antineoplastic drugs. <i>Cancer Treatment Reviews, 20</i>(2), 191-214.

Verstappen, C. C., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. <i>Drugs, 63</i>(15), 1549-1563.

Wichmann, M. W., Meyer, G., Adam, M., Hochtlen-Vollmar, W., Angele, M. K., Schalhorn, A., et al. (2003). Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. <i>Diseases of the Colon and Rectum, 46</i>(7), 875-887.

Wilkes, G. M., & Barton-Burke, M. (2007). <i>Oncology nursing drug handbook.</i> Sudbury, MA: Jones and Bartlett.

Wilson, C. J., Finch, C. E., & Cohen, H. J. (2002). Cytokines and cognition: The case for a head-to-toe inflammatory paradigm. <i>Journal of the American Geriatrics Society, 50</i>(12), 2041-2056.

Wong, E. T., & Berkenblit, A. (2004). The role of topotecan in the treatment of brain metastases. <i>Oncologist, 9</i>(1), 68-79.

Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. <i>Oncology Nursing Forum, 33</i>(3), 535-542.

Zaks-Zilberman, M., Zaks, T. Z., & Vogel, S. N. (2001). Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. <i>Cytokine, 15</i>(3), 156-165.